Skip to main content
SpringerLink
Log in

The ability to predict drug interactions mediated by active drug transport systems can help optimise pharmacotherapy

  • Drug Reactions and Interaction
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Fig. 2
Fig. 3

References

  1. DuBuske LM. The role of P-glycoprotein and organic anion-trans-porting polypeptides in drug interactions. Drug Saf 2005; 28(9): 789–801

    Article  PubMed  CAS  Google Scholar 

  2. Hansten P, Levy R. Role of P-glycoprotein and organic anion transporting polypeptides in drug absorption and distribution: focus on H1-receptor antagonists. Clin Drug Invest 2001; 21: 1–10

    Article  Google Scholar 

  3. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000; 38: 69–74

    PubMed  CAS  Google Scholar 

  4. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22: 137–40

    Article  PubMed  CAS  Google Scholar 

  5. Matheny CJ, Lamb MW, Brouwer KR, et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778–96

    Article  PubMed  CAS  Google Scholar 

  6. DuBuske LM. Drug transport systems. Pharm Perspect 2001: 3–14

  7. Dresser GK, Schwarz U, Leake B, et al. Grapefruit juice selectively inhibits OATP not P-glycoprotein. Drug Metab Rev 2000; 32 Suppl. 2: 193

    Google Scholar 

  8. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161–6

    PubMed  CAS  Google Scholar 

  9. Tirona RG, Kim RB. Pharmacogenomics of organic anion-trans-porting polypeptides (OATP). Adv Drug Deliv Rev 2002; 54: 1343–52

    Article  PubMed  CAS  Google Scholar 

  10. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189–99

    Article  PubMed  CAS  Google Scholar 

  11. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594–601

    Article  PubMed  CAS  Google Scholar 

  12. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237–42

    Article  PubMed  CAS  Google Scholar 

  13. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001; 11: 87–98 60

    PubMed  CAS  Google Scholar 

  14. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anti-cancer drugs. Eur J Pharm sci 2000; 11: 265–83

    Article  PubMed  CAS  Google Scholar 

  15. Rowinsky EK, Smith L, Wang YM, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by over-expression of both MDR1 and MRP. J Clin Oncol 1998; 16: 2964–76

    PubMed  CAS  Google Scholar 

  16. Allegra (fexofenadine) prescribing information. Kansas City (MO): Aventis Pharmaceuticals, 2000

  17. Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69: 114–21

    Article  PubMed  CAS  Google Scholar 

  18. Loi CM, Young M, Randinitis E, et al. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999; 37: 91–104

    Article  PubMed  CAS  Google Scholar 

  19. Hamman MA, Wang Z, Honig P, et al. Effects of acute and chronic Saint John’s wort (SJW) administration on fexofenadine (FEX) disposition [abstract]. Clin Pharmacol Ther 2001; 69: P53

    Article  Google Scholar 

  20. Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002; 41: 311–8

    Article  PubMed  CAS  Google Scholar 

  21. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11–20

    Article  PubMed  CAS  Google Scholar 

  22. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53

    Article  PubMed  CAS  Google Scholar 

  23. Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231–7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The ability to predict drug interactions mediated by active drug transport systems can help optimise pharmacotherapy. Drugs Ther. Perspect 22, 22–26 (2006). https://doi.org/10.2165/00042310-200622060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622060-00007

Search

Navigation